In summary, the pharmacological manipulation of lactylation via p300 inhibitors and HDAC3 activators represents a promising avenue for the mitigation of post-stroke injury and fatigue, with preclinical data supporting their efficacy and laying the groundwork for future translational studies (Figure 3). The gene discussed is HDAC3; the disease is Stroke.